SUPPRESSION OF THE IMMUNE-RESPONSE BY A SOLUBLE COMPLEMENT RECEPTOR OF LYMPHOCYTES-B
SUPPRESSION OF THE IMMUNE-RESPONSE BY A SOLUBLE COMPLEMENT RECEPTOR OF LYMPHOCYTES-B
复制标题
DOI：
10.1126/science.1718035
复制
发表时间：
1991-10-04
期刊：
影响因子：
56.9
通讯作者：
FEARON, DT
中科院分区：
文献类型：
--
作者：
HEBELL, T;AHEARN, JM;FEARON, DT
B淋巴细胞的CD 19-CR 2复合物含有参与两种宿主防御系统（免疫和补体系统）的蛋白质。免疫系统亚单位的配体CD 19未知，但补体受体亚单位CR2（CD 21）结合补体系统C3组分的活化片段，并可能介导补体的免疫增强作用。通过将受体的C3结合区与免疫球蛋白G1（IgG 1）融合制备重组可溶性CR2。当在免疫时给予小鼠时，（CR2）2-IgG 1嵌合体与细胞CR2竞争C3结合，并抑制对T细胞依赖性抗原的抗体应答。（CR 2）2-IgG 1的这种抑制作用证明了CD 19-CR 2复合物的B细胞活化功能，并提出了一种新的体液免疫抑制方法。
The CD19-CR2 complex of B lymphocytes contains proteins that participate in two host-defense systems, the immune and complement systems. The ligand for the subunit of the immune system, CD19, is not known, but the complement receptor subunit, CR2 (CD21), binds activation fragments of the C3 component of the complement system and may mediate immunopotentiating effects of complement. A recombinant, soluble CR2 was prepared by fusing the C3-binding region of the receptor to immunoglobulin G1 (IgG1). The (CR2)2-IgG1 chimera competed with cellular CR2 for C3 binding and suppressed the antibody response to a T cell-dependent antigen when administered to mice at the time of immunization. This inhibitory effect of (CR2)2-IgG1 demonstrates the B cell-activating function of the CD19-CR2 complex and suggests a new method for humoral immunosuppression.